US Patent 11834661 Angiotensinogen (AGT) iRNA compositions and methods of use thereof
Patent 11834661 was granted and assigned to Alnylam Pharmaceuticals on December, 2023 by the United States Patent and Trademark Office.
All edits
Edits on 7 Dec, 2023
Golden AI
Edits made to:
Infobox (+23 properties)
Article (+324 characters)
US Patent 11834661 Angiotensinogen (AGT) iRNA compositions and methods of use thereof
Article
Patent abstract
The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the AGT gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an AGT gene and to methods of preventing and treating an AGT-associated disorder, e.g., high blood pressure.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Donald Foster0
Gregory Hinkle0
Mark K. Schlegel0
Date of Patent
December 5, 2023
0Patent Application Number
172241790
Date Filed
April 7, 2021
0Patent Citations
Patent Primary Examiner
CPC Code
Find more entities like US Patent 11834661 Angiotensinogen (AGT) iRNA compositions and methods of use thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.